Evidence map›Paper›PMID 40867550›Full record

ArticleBiomolecules2025

In Silico and In Vivo Pharmacological Evaluation of Iridoid Compounds: Geniposide and Asperuloside Profile Study Through Molecular Docking Assay and in the

Mariana Uczay, Péterson Alves Santos, Pricila Pflüger, Gilsane von Poser, José Brea, Maria Isabel Loza, Patrícia Pereira, José Angel Fontenla

Abstract read
In one paragraph

Article in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mariana UczayGI-1684 Laboratory of Central Nervous System Pharmacology, Department of Pharmacology, Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain.
Péterson Alves SantosGI-1684 Laboratory of Central Nervous System Pharmacology, Department of Pharmacology, Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain.ORCID 0000-0003-3840-7343
Pricila PflügerGI-1684 Laboratory of Central Nervous System Pharmacology, Department of Pharmacology, Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain.ORCID 0000-0002-6067-1266
Gilsane von PoserLaboratory of Pharmacognosy, College of Pharmacy, Federal University of Rio Grande do Sul (UFRGS), Porto Alegre 91501-970, Brazil.
José BreaCenter for Research in Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela, 15782 Santiago de Compostela, Spain.ORCID 0000-0002-5523-1979
Maria Isabel LozaCenter for Research in Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela, 15782 Santiago de Compostela, Spain.
Patrícia PereiraLaboratory of Neuropharmacology and Preclinical Toxicology, Institute of Basic Health Sciences, Federal University of Rio Grande do Sul, Porto Alegre 90050-170, Brazil.
José Angel FontenlaGI-1684 Laboratory of Central Nervous System Pharmacology, Department of Pharmacology, Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain.ORCID 0000-0002-9758-676X

Funding

CNPq Program (Conselho Nacional de Desenvolvimento Científico e Tecnológico, Brazil This work was partially financed by CNPq ProgramFederal University of Rio Grande do Sul Program Postgraduate in Pharmacology and TherapeuticsUniversity of Santiago de Compostela (USC), Spain. Financial support through the Mobility Program for teachers from outside the European Higher Education Area (EHEA)
6 · The paper itself

Abstract

Iridoids are compounds recognized for their neuroprotective properties and their potential application in the treatment of neurodegenerative diseases. Geniposide (GP) and asperuloside (ASP) are iridoids that have demonstrated some biological activities. In this study, the potential neuroprotective effects of these iridoids were evaluated through in silico and in vivo assays, using

Indexed as

Caenorhabditis elegansIridoidsNeuroprotective AgentsAcetylcholinesteraseAnimalsMolecular Docking SimulationAcetylcholinesterasegeniposideIridoidsNeuroprotective AgentsasperulosideCaenorhabditis elegansgeniposideiridoidsmolecular dockingneurodegeneration

Identifiers

PMID40867550
PMCPMC12384043

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.